FDA approves GE visualization platform

Keith Moore | | Health Imaging | Screening
GE Healthcare has received FDA clearance of Ready View, a new MR advanced visualization platform to help clinicians process and analyze images.

A part of the Dexus workflow, Ready View is accessible through any PC, PACS or RIS workstation, providing physicians access to process and analyze images in any office, meeting room or at home.

The Ready View visualization platform provides a combination of protocols, applications and tools that enable quantified analysis. In addition to standard and advanced protocols, such as 4D review and image averaging, Ready View offers multiparametric protocols, such as brain oncology, knee and liver. Multiparametric protocols enable a workflow to process functional data from a single screen without having to leave a reading station, according to the Waukesha, Wis.-based company.

Keith Moore

Related Content

Abbreviated MRI protocols present suitable alternatives for liver cancer screening
Routine abdominal CTs offer insight into cardiovascular risk
Screening efforts have helped avert millions of cancer-related deaths in recent decades
What breast density status can tell us about cardiovascular risk
FDA clears AI tool that flags signs of heart disease in chest CT scans
Patients without PCPs struggle to access lung cancer screening, despite eligibility

Around the web

Radiology Business
AI can help radiology standardize image exam data labeling

To fully leverage today's radiology IT systems, standardization is a necessity. Steve Rankin, chief strategy officer for Enlitic, explains how artificial intelligence can help.

Radiology Business
The biggest obstacles facing radiology business managers in 2025

RBMA President Peter Moffatt discusses declining reimbursement rates, recruiting challenges and the role of artificial intelligence in transforming the industry.

Cardiovascular Business
New cardiac prevention paradigm explored in TRANSFORM trial using AI and CCTA

Deepak Bhatt, MD, director of the Mount Sinai Fuster Heart Hospital and principal investigator of the TRANSFORM trial, explains an emerging technique for cardiac screening: combining coronary CT angiography with artificial intelligence for plaque analysis to create an approach similar to mammography.